Wego Ortho

Note: Wego Ortho is part of the WEGO Group family. For surgical robotics products, see WEGO Surgery Robot, a separate WEGO Group subsidiary specializing in the MicroHand S laparoscopic robot system.

Wego Ortho stands as one of China’s largest orthopedic implant manufacturers, with product lines spanning spine, trauma, joint replacement, and sports medicine. Listed on the Shanghai Stock Exchange STAR Market in June 2021, the company has been actively expanding into the surgical robotics space through strategic partnerships and subsidiary development.

Company Overview

Originally established in 2005 as a subsidiary of Weigao Group, Wego Ortho has grown to become a broad-portfolio orthopedic medical device provider. The company achieved a significant milestone with its IPO on the STAR Market (Science and Technology Innovation Board) on June 30, 2021, raising approximately CNY 3.2 billion. Weigao Group, the parent company, was founded in 1988 and has evolved into one of China’s leading integrated medical device conglomerates.

The company maintains manufacturing facilities in Weihai, Shandong Province, equipped with advanced machining capabilities. Its product portfolio includes Class I, II, and III medical devices, with over 160 Class III medical device registration certificates as of 2025.

Core Products

Orthopedic Implants

Wego Ortho offers a broad range of orthopedic implants across major clinical categories:

• Spine Products: Pedicle screw systems, interbody fusion devices, cervical fixation systems
• Trauma Products: Locking plates, intramedullary nails, external fixation devices
• Joint Products: Hip and knee replacement systems, including 3D-printed implants
• Sports Medicine: Suture anchors, interference screws, soft tissue repair devices

The company has been expanding its high-end product development, including bone trabecular fusion cages, new-generation 3D-printed hip joint systems, and bioinducible absorbable suture anchors.

Technology & Innovation

Wego Ortho has been strategically positioning itself at the intersection of traditional implants and digital surgery technologies. Key technological initiatives include:

• 3D Printing: Development of patient-specific implants using additive manufacturing
• Surgical Navigation: Integration with navigation systems for precision implant placement
• AI Applications: Exploring artificial intelligence for surgical planning and implant matching

The company holds hundreds of patents across its product lines and maintains collaborative relationships with leading orthopedic research institutions in China.

Surgical Robotics Strategy

While primarily an implant manufacturer, Wego Ortho has been actively expanding into the surgical robotics domain through multiple approaches:

Strategic Partnership with Tinavi

In August 2022, Wego Ortho signed a strategic cooperation agreement with Tinavi Medical Technology (688277.SH), China’s leading orthopedic surgical robot company. This partnership focuses on:

• Joint R&D of orthopedic surgical robot applications
• Integration of Wego implants with Tinavi’s TiRobot systems
• Co-development of integrated surgical solutions

Investment in Rehabilitation Robotics

In February 2022, Wego Ortho made a strategic investment in Milebot, a rehabilitation exoskeleton robot company. The companies also established a joint venture to develop:

• Intelligent orthopedic treatment devices
• Orthopedic rehabilitation robots
• Orthopedic rehabilitation assessment systems

In-House Robot Development

Within the broader Weigao Group structure, Weihai Wego Orthopedic Robot Co., Ltd. has been developing proprietary orthopedic surgical robot systems focusing on joint replacement procedures (hip and knee). The company is working toward achieving independent intellectual property rights and domestic component sourcing for its orthopedic robot systems.

Market Presence

Wego Ortho ranks among China’s top orthopedic device companies by market share. Following national volume-based procurement (VBP) policies for orthopedic implants, the company has expanded its market presence, particularly in the joint replacement and spine segments.

The company benefits from Weigao Group’s extensive distribution network covering major hospitals across China. As a domestic leader, Wego Ortho has been gaining market share from international competitors as the import substitution trend accelerates in China’s orthopedic market.

Key Milestones

• 2005: Established as Shandong Wego Orthopedic Material Co., Ltd.
• 2021: IPO on Shanghai STAR Market (688161.SH)
• 2022: Strategic partnership with Tinavi for orthopedic robot development
• 2022: Strategic investment in Milebot for rehabilitation robot development
• 2025: Continued expansion of Class III medical device registrations

Frequently Asked Questions

What is Wego Ortho’s core business?

Wego Ortho is primarily an orthopedic implant manufacturer, producing spine, trauma, joint replacement, and sports medicine devices. The company is expanding into surgical robotics through partnerships and subsidiary development.

Is Wego Ortho publicly traded?

Yes, Wego Ortho is listed on the Shanghai Stock Exchange STAR Market under the ticker 688161.SH since June 2021.

Does Wego Ortho have its own surgical robot?

Wego Ortho is developing orthopedic surgical robots through its subsidiary (Weihai Wego Orthopedic Robot Co., Ltd.) and has strategic partnerships with Tinavi for robot-assisted orthopedic surgery solutions. As of early 2026, specific NMPA approval status for proprietary orthopedic robot products requires verification.

What is the relationship between Wego Ortho and Weigao Group?

Wego Ortho is a subsidiary of Weigao Group, one of China’s largest medical device conglomerates. Weigao Group (1066.HK) is separately listed on the Hong Kong Stock Exchange and has multiple subsidiaries across different medical device segments.